Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Danaher Corporation DHR-PB NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
62/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Danaher Corporation (DHR-PB) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 5 Buy, 3 Hold.

DHR-PB Analyst Ratings

Buy
8
Ratings
5 Buy
3 Hold
Based on 8 analysts giving stock ratings to Danaher Corporation in the past 3 months
Rating breakdown
Buy
5 63%
Hold
3 38%
63%
Buy
5 analysts
38%
Hold
3 analysts
0%
Sell
0 analysts

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message